Comparative Efficacy of Ongericimab Versus Six PCSK9 Inhibitors in Treating Hypercholesterolemia or Mixed Dyslipidemia: A Network Meta-Analysis
Author(s)
Zhaoli Tang, MD MSPH1, Yun Liu, PhD1, Jian Ming, PhD2, Jun Liu, PhD1, Peng Xie, MSc3.
1IQVIA, Shanghai, China, 2Fudan University, Shanghai, China, 3Chongqing Bochuang Pharmaceutical Co., Ltd., Chongqing, China.
1IQVIA, Shanghai, China, 2Fudan University, Shanghai, China, 3Chongqing Bochuang Pharmaceutical Co., Ltd., Chongqing, China.
OBJECTIVES: Ongericimab is a novel PCSK9 inhibitor for the treatment of hypercholesterolemia and mixed dyslipidemia. This study aimed to assess the relative lipid-lowering efficacy of ongericimab compared with other PCSK9 inhibitors through a network meta-analysis (NMA).
METHODS: We conducted a systematic literature review (SLR) to identify phase 3 randomized controlled trials (RCTs) of ongericimab and six other PCSK9 inhibitors (evolocumab, alirocumab, tafolecimab, recaticimab, ebronucimab, and inclisiran) assessing efficacy in adult patients with hypercholesterolemia or mixed dyslipidemia, compared with background lipid-lowering therapies. A feasibility assessment supported similarity and consistency assumptions across the comparisons between studies. The NMA was conducted using a frequentist framework to estimate relative percentage changes from baseline in low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) between ongericimab and other PCSK9 inhibitors. In the base-case analysis, the follow-up duration was limited to 48 or 52 weeks to ensure comparability and reflect sustained efficacy; Ongericimab dosing frequency was limited to every 4 weeks (Q4W), given its potential to enhance long-term adherence and reduce treatment burden in lipid management. Alternative follow-up periods (12 and 24 weeks) and ongericimab dosing frequency (every 2 weeks) were evaluated in scenario analyses.
RESULTS: Nineteen RCTs met inclusion criteria. Of these, 18 (95%) reported LDL-C reduction outcomes and 15 (79%) reported Lp(a) reduction outcomes. Ongericimab demonstrated superior efficacy in Lp(a) reduction compared to all other PCSK9 inhibitors except tafolecimab, with mean differences of 2-12%, statistically significant versus evolocumab, alirocumab, and recaticimab. Similarly, ongericimab was superior in LDL-C reduction than all except tafolecimab and recaticimab, with mean differences of 2-20%. Scenario analyses demonstrated consistent trends in treatment effects.
CONCLUSIONS: Ongericimab demonstrated superior efficacy in reducing LDL-C and Lp(a) levels compared with most existing PCSK9 inhibitors. These findings may inform clinical decisions and support formulary positioning in lipid-lowering treatment strategies.
METHODS: We conducted a systematic literature review (SLR) to identify phase 3 randomized controlled trials (RCTs) of ongericimab and six other PCSK9 inhibitors (evolocumab, alirocumab, tafolecimab, recaticimab, ebronucimab, and inclisiran) assessing efficacy in adult patients with hypercholesterolemia or mixed dyslipidemia, compared with background lipid-lowering therapies. A feasibility assessment supported similarity and consistency assumptions across the comparisons between studies. The NMA was conducted using a frequentist framework to estimate relative percentage changes from baseline in low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) between ongericimab and other PCSK9 inhibitors. In the base-case analysis, the follow-up duration was limited to 48 or 52 weeks to ensure comparability and reflect sustained efficacy; Ongericimab dosing frequency was limited to every 4 weeks (Q4W), given its potential to enhance long-term adherence and reduce treatment burden in lipid management. Alternative follow-up periods (12 and 24 weeks) and ongericimab dosing frequency (every 2 weeks) were evaluated in scenario analyses.
RESULTS: Nineteen RCTs met inclusion criteria. Of these, 18 (95%) reported LDL-C reduction outcomes and 15 (79%) reported Lp(a) reduction outcomes. Ongericimab demonstrated superior efficacy in Lp(a) reduction compared to all other PCSK9 inhibitors except tafolecimab, with mean differences of 2-12%, statistically significant versus evolocumab, alirocumab, and recaticimab. Similarly, ongericimab was superior in LDL-C reduction than all except tafolecimab and recaticimab, with mean differences of 2-20%. Scenario analyses demonstrated consistent trends in treatment effects.
CONCLUSIONS: Ongericimab demonstrated superior efficacy in reducing LDL-C and Lp(a) levels compared with most existing PCSK9 inhibitors. These findings may inform clinical decisions and support formulary positioning in lipid-lowering treatment strategies.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO77
Topic
Clinical Outcomes, Epidemiology & Public Health, Study Approaches
Topic Subcategory
Comparative Effectiveness or Efficacy
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Diabetes/Endocrine/Metabolic Disorders (including obesity), Geriatrics, No Additional Disease & Conditions/Specialized Treatment Areas